Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860563 | 0.92 | TYMP (0.40) | ADORA1P2RY12POLBP2RY2P2RY1 | |
| SCHEMBL5694043 | 0.90 | SLC29A1 (0.38) | SLC29A1P2RY1 | |
| SCHEMBL20341130 | 0.89 | ADORA1 (0.40) | ADORA1P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL11055621 | 0.88 | P2RY12 (0.40) | ADORA1P2RY12POLB | |
| SCHEMBL5694262 | 0.87 | P2RY12 (0.37) | P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL4727404 | 0.87 | ADORA1 (0.46) | ADORA1POLBSLC29A1 | |
| SCHEMBL4727394 | 0.87 | ADORA1 (0.46) | ADORA1POLBSLC29A1 | |
| SCHEMBL23621360 | 0.86 | P2RY12 (0.44) | ADORA1P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL20908639 | 0.86 | P2RY12 (0.44) | ADORA1P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL23621322 | 0.86 | P2RY12 (0.44) | ADORA1P2RY12P2RY2P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2023-06-06 | — | — | US | disclosed |
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2023-06-06 | — | — | US | disclosed |
| US-20220017561-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2022-01-20 | — | — | US | disclosed |
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2021-07-06 | — | — | US | disclosed |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2020-08-13 | — | — | US | disclosed |
| US-10562929-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | INVIVOGEN (FR) | 2018-07-03 | — | — | US | disclosed |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | INVIVOGEN (FR) | 2018-07-03 | — | — | US | disclosed |
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2016-12-15 | — | — | US | disclosed |
| WO-2016096174-A1 | FLUORINATED CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | ADORA1 300/4885P2RY12 908/4885POLB 137/4885 |
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | ADORA1 300/4885P2RY12 908/4885POLB 137/4885 |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | ADORA1 300/4885P2RY12 908/4885POLB 137/4885 |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | ADORA1 300/4885P2RY12 908/4885POLB 137/4885 |
| US-20220017561-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | ADORA1 300/4885P2RY12 908/4885POLB 137/4885 |
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | ADORA1 300/4885P2RY12 908/4885POLB 137/4885 |
| US-10562929-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | ADORA1 300/4885P2RY12 908/4885POLB 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.